| Liu, Hui Liang |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
NCT04610970: A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） |
|
|
| Recruiting | 2 | 93 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diffuse Large B-cell Lymphoma | 03/22 | 06/22 | | |
NCT04787328: A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) |
|
|
| Recruiting | 2 | 30 | RoW | HA121-28 tablets | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Medullary Thyroid Carcinoma | 03/23 | 03/25 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT05441761: Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL |
|
|
| Recruiting | 1/2 | 60 | RoW | liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Treatment, Peripheral T-cell Lymphoma | 05/25 | 05/25 | | |
NCT04537442: Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | IM21 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Multiple Myeloma | 12/22 | 03/23 | | |
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations |
|
|
| Active, not recruiting | 1 | 200 | Europe, Japan, US, RoW | LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab | Eli Lilly and Company, Loxo Oncology, Inc. | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | 07/23 | 05/25 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 26 | RoW | BL-M11D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | 08/25 | 08/25 | | |
NCT05278507: Comparing Arrow PICC Catheters w/ Arrowga+rd Blue Advanced Protection Performance and Safety to Unprotected PICC's |
|
|
| Recruiting | N/A | 444 | RoW | Arrowga+rd Blue Advance Protection PICC Placement, Sham Comparator PICC placement | Teleflex | Peripherally Inserted Central Catheter | 06/23 | 06/23 | | |
| Zhou, Wei |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
GM-seq, NCT05415670: Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing |
|
|
| Recruiting | N/A | 120 | RoW | Whole-genome Methylation Sequencing(GM-seq) | Geneplus-Beijing Co. Ltd., Beijing Hospital, Emergency General Hospital | Pulmonary Nodule, Solitary, Whole-genome Methylation Sequencing | 06/25 | 06/25 | | |
| Recruiting | N/A | 200 | US | SelfWrap Bioabsorbable Perivascular Wrap, SelfWrap, Untreated AVF Control, Standard of Care | VenoStent | Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency | 06/25 | 12/27 | | |
| Recruiting | N/A | 450 | US | Alto Abdominal Stent Graft System, FDA Approved EVAR AAA Graft Systems | Endologix | AAA, AAA - Abdominal Aortic Aneurysm | 12/28 | 12/28 | | |
| Qi, Hongbo bo |
| No trials found |
| He, Fang |
| No trials found |
| Zhong, Qimei |
| No trials found |
| Liu, Zhaoming |
| No trials found |
| Li, Haoran |
| No trials found |
